# Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension

> **NCT00246636** · PHASE4 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 167 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** Antara (fenofibrate) + Lovaza
- **DRUG:** Antara (fenofibrate)

## Key facts

- **NCT ID:** NCT00246636
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2007-02
- **Final completion:** 2007-03
- **Target enrollment:** 167 (ACTUAL)
- **Last updated:** 2009-12-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246636, "Evaluation of Efficacy and Safety of Omacor (Omega-3-acid Ethyl Esters) as Add-on Therapy in Hypertriglyceridemic Subjects Treated With Antara (Fenofibrate) Followed by an 8-week Extension". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00246636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*